Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Clinical Pharmacology
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Clinical Pharmacology
    Oral Sodium Picosulphate Alleviates Chronic, Functional Constipation: Presented at GASTRO 2009 (UEGW/WCOG) - (DGDispatch)
    FDA Approves Low-Dose Local Oestrogen Therapy for the Treatment of Atrophic Vaginitis Due to Menopause - (DGNews)
    Colon Cell-Collecting Device Could Aid Colorectal Cancer Screening: Presented at GASTRO 2009 (UEGW/WCOG) - (DGDispatch)
    PPIs Cut Upper GI Bleeding Risk in Half During Antiplatelet Therapy: Presented at GASTRO 2009 (UEGW/WCOG) - (DGDispatch)
    Abacavir-Lamivudine Combination Has Worse Clinical Outcomes Than Tenofovir DF-Emtricitabine Combination in Patients With High HIV-1 Loads - (DGNews)

    News archive

     Recent webcasts/CME - Clinical Pharmacology
      Multiple Sclerosis: Tempering Disabilities and Decline--Fundamentals for Managed Markets
      Evolving Strategies for Chronic Idiopathic Thrombocytepenic Purpura
      Advances in the Treatment of NHL: Updates from the 2009 Pan Pacific Lymphoma Conference
      Fibromyalgia: The Patient Who Hurts Too Much
      Patient-Centered Approaches to the Evaluation and Management of Atrial Fibrillation

      Webcasts/CME archive

       Recent cases - Clinical Pharmacology
        Ulceration Of The Oral Mucosa Induced By Antidepressant Medication: A Case Report
        Dual Antiplatelet Therapy in Coronary Artery Disease: A Case-Based Approach
        Persistent Orocutaneous and Anal Fistulae Induced by Nicorandil: A Case Report
        Successful Use of Single-Dose Rituximab for the Maintenance of Remission in a Patient with Steroid-Resistant Nephrotic Syndrome
        Recurrent Stupor Associated with Chronic Valproic Acid Therapy and Hyperammonemia

        Cases archive
          




        my personal edition > clinical pharmacology > news
        divider

          E-Mail this DGReview to a colleague

        DGReview


        Risk of Leflunomide-Associated Pancytopenia Appears Greater With Concomitant Methotrexate Treatment and Increased Patient Age

        A DGReview of :"Leflunomide-Associated Pancytopenia With or Without Methotrexate"
        Annals of Pharmacotherapy

        07/02/2004
        By Jill Taylor


        Leflunomide treatment is associated with severe pancytopaenia, the risk of which is increased when the drug is combined with methotrexate and when given to older patients, according to Australian researchers.

        "Because of the long half-life of leflunomide, myelosuppression can persist after the drug is discontinued," said Jonathan Chan, MB, BS, MRCP, and colleagues of Princess Alexandra Hospital, Brisbane, Queensland. "Regular monitoring is essential for this serious adverse effect, even in patients who have been treated for years."

        Previous clinical trials have demonstrated leflunomide to be superior to placebo and as effective as methotrexate or sulfasalazine. Additionally, the combination of leflunomide and methotrexate has been shown to be effective as add-on therapy in patients with active rheumatoid arthritis (RA) who have inadequate response to methotrexate alone.

        However, the safety of leflunomide in combination with other disease-modifying antirheumatic drugs has not been fully evaluated.

        In a recently published report, the researchers report 5 cases of severe pancytopaenia associated with concomitant leflunomide and methotrexate in patients admitted to the Princess Alexandra Hospital and review 13 additional cases of pancytopaenia with leflunomide, combined with methotrexate in 9 cases, reported since 2000.

        Among the cases, 17 patients were being treated for RA, and 1 for systemic lupus erythematosus. Patient age ranged from 18 to 79 years, with all but 3 patients aged 60 years and over.

        The time to onset of pancytopaenia was variable, ranging from 11 days to 4 years. Pancytopaenia was typically severe, requiring hospital admission for at least 14 patients. Sepsis was recorded in 6 cases.

        Among the 5 recorded deaths, 4 of the patients had been treated with concomitant methotrexate during leflunomide therapy. In 1 case, the patient had been stable for 4 years during treatment with leflunomide, methotrexate, and hydroxychloroquine, prior to fatal pancytopaenia triggered by acute renal failure.

        Information regarding routine blood cell count monitoring or measurement of leflunomide concentrations was not available.

        Analysis showed an association between leflunomide treatment, with or without methotrexate, and severe pancytopaenia, with a probable causal association in 5 cases and possible association in the remainder suggested by the Naranjo probability scale.

        The researchers note that the global updated leflunomide product information advises monitoring the complete blood cell count monthly for the first 6 months, and every 6?8 weeks thereafter.

        "If leflunomide is used with concomitant methotrexate, monitoring should be performed monthly," they advised.

        Ann Pharmacother 2004 Jul;38:7:1206-11. Epub 2004 Jun 08. "Leflunomide-Associated Pancytopenia With or Without Methotrexate"

        E-Mail this DGReview to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send